Marchetti G, Vitolo E, Di Francesco G F, Cavallaro B, Sponzilli C
Arch Int Pharmacodyn Ther. 1983 Dec;266(2):250-63.
Potassium canrenoate (KCR) is widely used in cardiac patients as an aldosterone antagonist, antiarrhythmic and diuretic drug. According to experimental and clinical studies it can also elicit an inotropic action. It is not clear, however, whether this inotropic activity occurs in the absence of any treatment or after the myocardial contractility has already been improved with digitalis. In order to evaluate a possible interaction of this drug with digitalis we administered KCR intravenously to 41 anaesthetized dogs either untreated or treated with digitalis, in which aortic and left ventricular pressures were recorded and myocardial contractility was evaluated by calculating in real time the first derivative of ventricular pressure (Formula: see text) max and two other contractility indexes (Formula: see text) max and V.max. The results obtained showed that KCR given at doses of 10, 20 and 30 mg/kg i.v. did not elicit any inotropic effect in dogs not previously digitalized. 100 mg/kg i.v. first depressed cardiac contractility and then increased it. After cardiac performance had been improved by digitalis, KCR further increased all contractility indexes significantly. These results could explain previous observations that no inotropic effect was observed in human subjects not treated with digitalis after treatment with KCR.
安体舒通钾(KCR)作为醛固酮拮抗剂、抗心律失常药和利尿药,在心脏病患者中广泛使用。根据实验和临床研究,它还可引发正性肌力作用。然而,尚不清楚这种正性肌力活性是在未进行任何治疗的情况下出现,还是在心肌收缩力已用洋地黄改善之后出现。为了评估该药物与洋地黄可能的相互作用,我们对41只麻醉犬静脉注射KCR,这些犬未接受治疗或已用洋地黄治疗,记录主动脉和左心室压力,并通过实时计算心室压力的一阶导数(公式:见正文)max以及另外两个收缩力指标(公式:见正文)max和V.max来评估心肌收缩力。所得结果表明,静脉注射剂量为10、20和30mg/kg的KCR对未预先用洋地黄处理的犬未引发任何正性肌力作用。静脉注射100mg/kg时,首先使心脏收缩力降低,然后使其增加。在用洋地黄改善心脏功能后,KCR可显著进一步增加所有收缩力指标。这些结果可以解释先前的观察结果,即未用洋地黄治疗的人类受试者在用KCR治疗后未观察到正性肌力作用。